HUTCHMED (China) Ltd
About HUTCHMED (China) Ltd
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $548.5M
- Net income
- $456.9M
- Total assets
- $1.8B
- Market cap
- $1.9B
Source: SEC EDGAR · updated Jun 8, 2026
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.9B
- Shares outstanding
- 172.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 17, 2016
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $456.9M in FY2025.
- Trading 44% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review HUTCHMED (China) Ltd.
Write a review
News about HUTCHMED (China) Ltd
News & sentiment via Polygon.io
